Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)

BACKGROUND: Multiple vaccine candidates against COVID-19 are currently being evaluated. We evaluate the safety and immunogenicity protein of a novel SARS-CoV-2 virus receptor-binding domain (RBD) vaccine. METHODS: A phase 1-2, randomised, double-blind, placebo-controlled trial was carried out in “Sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Bernal, Francisco, Ricardo-Cobas, Maria C., Martín-Bauta, Yenima, Navarro-Rodríguez, Zadis, Piñera-Martínez, Marjoris, Quintana-Guerra, Joel, Urrutia-Pérez, Karen, Urrutia-Pérez, Klaudia, Chávez-Chong, Cristina O., Azor-Hernández, Jorge L., Rodríguez-Reinoso, José L., Lobaina-Lambert, Leonardo, Colina-Ávila, Elizabeth, Bizet-Almeida, Jacqueline, Rodríguez-Nuviola, Jeniffer, del Valle-Piñera, Sergio, Ramírez-Domínguez, Mayara, Tablada-Ferreiro, Elisangela, Alonso-Valdés, Marel, Lemos-Pérez, Gilda, Guillén-Nieto, Gerardo E., Palenzuela-Díaz, Ariel, Noa-Romero, Enrique, Limonta-Fernández, Miladys, Fernández-Ávila, Juan M., Ali-Mros, Nabil A., del Toro-Lahera, Lianne, Remedios-Reyes, Rossana, Ayala-Ávila, Marta, Muzio-González, Verena L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994669/
https://www.ncbi.nlm.nih.gov/pubmed/35434578
http://dx.doi.org/10.1016/j.eclinm.2022.101383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994669/
https://www.ncbi.nlm.nih.gov/pubmed/35434578
http://dx.doi.org/10.1016/j.eclinm.2022.101383

Ejemplares similares